Rick Bucala
Citation Information: J Clin Invest. 2014;124(5):1887-1888. https://doi.org/10.1172/JCI75224.
Rick Bucala
Published May 1, 2014
Citation Information: J Clin Invest. 2014;124(5):1887-1888. https://doi.org/10.1172/JCI75224.
Abstract
The inactivation of NO by advanced glycation endproducts (AGEs), which accumulate on tissue proteins as a function of age and hyperglycemia, focused attention on the role of these ubiquitous posttranslational modifications in acquired impairments of vascular reactivity and other signaling processes. This observation occurred during a watershed period of basic and translational research in glycation that encompassed new pathologic phenomena and novel intervention strategies. How has the AGE paradigm for the tissue complications of aging and diabetes fared since the identification of the link between these glycation products and NO inactivation, and what lessons may be offered for future investigations?
Authors
Rick Bucala
Full Text PDF | Download (587.31 KB)
Copyright © 2024 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)